stockrowX4 Pharmaceuticals, Inc.
XFOR Healthcare Biotechnology
X4 Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.1 million, up 1,273.2% from fiscal 2024.
- Revenue
- +63.1%
- EPS
- +76.9%
- Free cash flow
- +27.5%
- Total debt
- +1.24%
Quarter to September 2026, against a year earlier
Follow XFOR
Alert me
X4 Pharmaceuticals, Inc. (XFOR) EV/Sales
As of 6 November 2026, X4 Pharmaceuticals, Inc. (XFOR) trades at a EV/Sales of 17.0×. Over the past ten years it has ranged from −1.4× (February 2026) to 45.7× (May 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.2× | — |
| FY2024 | 21.9× | — |
| FY2020 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 15.2× | (47.75%) |
| Jun 2026 | 29.0× | (28.41%) |
| Mar 2026 | 40.5× | — |
| Dec 2025 | −0.2× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SCTX Scribe Therapeutics Inc. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. compare | 0.8× |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| AGEN Agenus Inc. compare | 3.2× |
| XFOR X4 Pharmaceuticals, Inc. | 17.0× |
| PROK ProKidney Corp. compare | 40.7× |
| BNTC Benitec Biopharma Limited compare | 3,500× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)